Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Carbamazepine-induced hepatitis].

J W Haukeland1, J Jahnsen, N Raknerud

  • 1Avdeling for fordøyelsessykdommer Medisinsk klinikk, Aker Sykehus 0514 Oslo. johnwilly@os.telia.no

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|January 6, 2001
PubMed
Summary

Carbamazepine can cause liver damage (hepatitis). Discontinuing the drug quickly leads to recovery, highlighting the importance of monitoring patients for this adverse effect.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Separate Gut Plasma Cell Populations Produce Auto-Antibodies against Transglutaminase 2 and Transglutaminase 3 in Dermatitis Herpetiformis.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2024
Same author

Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease.

Journal of Crohn's & colitis·2020
Same author

Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character).

Scandinavian journal of gastroenterology·2020
Same author

Whole Blood Profiling of T-cell-Derived microRNA Allows the Development of Prognostic models in Inflammatory Bowel Disease.

Journal of Crohn's & colitis·2020
Same author

Scientific Business Abstracts of the 112th Annual Meeting of the Association of Physicians of Great Britain and Ireland.

QJM : monthly journal of the Association of Physicians·2019
Same author

Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.

Journal of internal medicine·2019

Area of Science:

  • Hepatology
  • Pharmacology
  • Toxicology

Background:

  • Carbamazepine is a widely used medication with known hepatotoxic potential.
  • Clinicians must be aware of carbamazepine-induced liver injury as a significant adverse effect.

Observation:

  • Presents three cases of carbamazepine-induced hepatitis.
  • Patients exhibited clinical and biochemical evidence of liver damage.

Findings:

  • Hepatitis resolved promptly upon cessation of carbamazepine therapy.
  • Alternative causes of hepatitis were ruled out in all cases.

Implications:

  • Reviews existing literature on carbamazepine-induced hepatitis.
  • Discusses potential mechanisms of drug-induced liver injury, focusing on hepatic metabolism.
  • Emphasizes the critical role of a comprehensive medication history in diagnosing liver disease.
  • While prognosis is generally favorable, fatal outcomes have been documented.

Related Experiment Videos